丹红注射液和川芎嗪注射液治疗缺血性脑卒中疗效的系统评价及其药物经济学分析

Systematic evaluation of danhong injection and ligustrazine injection in the treatment of ischemic stroke and its pharmacoeconomic analysis

目的系统评价丹红注射液(Danhong Injection,DI)和川芎嗪注射液(ligustrazine injection,LI)治疗缺血性脑卒中的疗效,并分析其经济性。方法检索2007年1月1日-2017年12月30日国内外中、英文数据库,收集临床使用DI对比LI治疗缺血性脑卒中的相关文献。采用Rev Man 5.3软件对符合纳排标准的研究进行统计分析,并进行药物经济学评价。结果共纳入18篇文献,Meta分析结果显示:在治疗缺血性中风有效率、改善神经功能缺损、降低血浆黏度、降低低切/高切全血黏度方面,DI组均优于LI组(P<0.01);药物经济学分析结果显示:在治疗缺血性脑卒中的疗效方面,DI每增加1个疗效较LI需多花1.11元。根据WHO关于药物经济学评价的推荐意见,DI更具成本-效果优势。结论DI在治疗缺血性脑卒中的疗效和经济性均优于LI。

Objective To systematically evaluate the efficacy of Danhong Injection(DI)and ligustrazine injection(LI)in the treatment of ischemic stroke and analyze its pharmacoeconomic evaluation.Methods The Chinese and English databases from Jan.1st,2007 to Dec.30th,2017 were retrieved to collect relevant literatures on the treatment of ischemic stroke with DI and LI.Rev Man 5.3 software was used for statistical analysis and pharmacoeconomic evaluation.Results 18 studies were included.Meta-analysis showed that DI was superior to LI in the treatment of ischemic stroke in terms of effective rate,neurological deficits,and plasma viscosity(P<0.01).Pharmacoeconomic analysis showed that DI costs 1.11 yuan more for each additional curative effect than LI.According to WHO′s recommendation on pharmacoeconomic evaluation,DI has more cost-effectiveness advantages.Conclusion DI is superior to LI in efficacy and economy in the treatment of ischemic stroke.